Hospital
Metropolitan Hospital
Metropolitan Hospital was paid $100.96M by Medicaid between Jan 2018 and Dec 2024, across 654 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 10% of everything it billed.
33Billing provider infoMETROPOLITAN HOSPITAL
WYOMING, MI 49519
WYOMING, MI 49519
33aNPI1619923919assigned 05/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$100.96M
24GClaims3,651,917
24DCodes billed654
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#7 of 86
Median peer was paid$21.55M
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RUSSIAN, MISTY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 389,418 | $12.25M | |
| 2019 | 400,007 | $10.90M | |
| 2020 | 462,286 | $11.95M | |
| 2021 | 642,050 | $17.74M | |
| 2022 | 649,884 | $17.57M | |
| 2023 | 609,860 | $16.42M | |
| 2024incomplete | 498,412 | $14.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10% | 311,305 | 270,206 | $10.24M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.6% | 207,425 | 187,382 | $8.73M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.5% | 143,036 | 130,377 | $8.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.0% | 27,062 | 25,658 | $5.04M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.9% | 32,843 | 31,368 | $3.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 9,435 | 8,969 | $3.56M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.9% | 39,268 | 23,771 | $1.92M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 20,783 | 18,819 | $1.82M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.8% | 40,150 | 23,969 | $1.80M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 24,979 | 23,889 | $1.79M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.7% | 33,948 | 20,423 | $1.67M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 15,184 | 9,289 | $1.43M |
642 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.4% | 26,030 | $1.41M |
| 99204 | Doctor's office visit, new patient (more involved) | 1.3% | 17,031 | $1.33M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.2% | 22,857 | $1.20M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 1.1% | 19,216 | $1.10M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 10,818 | $1.06M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.0% | 11,696 | $1.01M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,656 | $999K |
| 59426 | <1% | 1,156 | $972K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14,958 | $940K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 11,141 | $910K |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 1,224 | $897K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 5,206 | $894K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,958 | $845K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,334 | $812K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,953 | $793K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 75,419 | $781K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14,558 | $758K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 3,141 | $700K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 779 | $687K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 22,798 | $676K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 36,594 | $648K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,093 | $634K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 22,254 | $598K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,442 | $590K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 14,167 | $571K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,812 | $559K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 541 | $522K |
| 90670 | <1% | 13,541 | $483K | |
| 93975 | <1% | 6,653 | $482K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 8,081 | $472K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,920 | $468K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,963 | $468K |
| 99223 | Prolong inpt eval add15 m | <1% | 4,540 | $457K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,675 | $437K |
| 76830 | Ultrasound, transvaginal | <1% | 9,275 | $424K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 10,246 | $422K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,270 | $411K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,779 | $373K |
| 80061 | Lipid panel | <1% | 40,102 | $373K |
| 99385 | <1% | 6,400 | $367K | |
| 71045 | Radiologic examination, chest; single view | <1% | 20,219 | $367K |
| 99205 | Prolong outpt/office vis | <1% | 3,620 | $358K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,307 | $350K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,854 | $344K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 173 | $329K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,719 | $327K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 9,499 | $324K |
| 90651 | <1% | 7,391 | $321K | |
| 87428 | <1% | 15,008 | $306K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,529 | $299K |
| 90677 | <1% | 2,853 | $283K | |
| 90750 | <1% | 2,048 | $276K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,801 | $266K |
| 99381 | <1% | 5,458 | $262K | |
| 59430 | <1% | 1,289 | $262K | |
| 86900 | <1% | 9,099 | $256K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,233 | $255K |
| 59025 | Fetal non-stress test | <1% | 5,806 | $253K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,508 | $246K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 44,968 | $245K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,346 | $244K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 11,291 | $241K |
| 80053 | Comprehensive metabolic panel | <1% | 79,854 | $231K |
| 76801 | <1% | 4,303 | $228K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,069 | $226K |
| 94060 | <1% | 3,458 | $225K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 10,078 | $216K |
| 17110 | <1% | 5,017 | $213K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 3,618 | $212K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,223 | $212K |
| 99496 | <1% | 2,810 | $209K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16,373 | $208K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,556 | $200K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 3,523 | $199K |
| 82947 | <1% | 18,632 | $193K | |
| 99383 | <1% | 3,644 | $192K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15,312 | $192K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,693 | $186K |
| 58571 | <1% | 81 | $185K | |
| 64615 | <1% | 2,038 | $184K | |
| 90686 | <1% | 21,176 | $181K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 140 | $180K |
| 99460 | <1% | 3,335 | $179K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 116,129 | $176K |
| 20610 | <1% | 2,532 | $175K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,256 | $171K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 3,905 | $165K |
| 90620 | <1% | 3,590 | $164K | |
| 99386 | <1% | 2,385 | $159K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,992 | $157K |
| 99384 | <1% | 2,738 | $156K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 407 | $148K |
| 99495 | <1% | 2,371 | $146K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,053 | $145K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 11,636 | $144K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,998 | $142K |
| 99382 | <1% | 2,753 | $141K | |
| 99220 | <1% | 1,424 | $132K | |
| 90716 | <1% | 8,158 | $131K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,056 | $131K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,320 | $130K |
| 97161 | <1% | 3,030 | $130K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 185,315 | $129K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,584 | $126K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,342 | $123K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 9,700 | $119K |
| 93971 | <1% | 3,908 | $116K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 29,414 | $112K |
| 97162 | <1% | 2,607 | $107K | |
| 96367 | <1% | 2,480 | $107K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 1,307 | $106K |
| 76642 | <1% | 3,795 | $106K | |
| 54150 | <1% | 1,485 | $104K | |
| 90734 | <1% | 6,511 | $102K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,450 | $101K |
| 90732 | <1% | 1,318 | $100K | |
| 71250 | <1% | 2,837 | $98K | |
| 76536 | <1% | 3,035 | $96K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,390 | $95K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,974 | $94K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35,984 | $94K |
| 93458 | <1% | 130 | $93K | |
| 76770 | <1% | 2,589 | $89K | |
| 59514 | <1% | 111 | $89K | |
| 47562 | <1% | 27 | $88K | |
| 95811 | <1% | 400 | $87K | |
| 95806 | <1% | 1,767 | $87K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,506 | $86K |
| 86780 | <1% | 10,569 | $82K | |
| G9002 | Coordinated care fee, maintenance rate | <1% | 5,232 | $82K |
| 58662 | <1% | 63 | $82K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,496 | $76K |
| 91320 | <1% | 715 | $74K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,877 | $71K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,204 | $70K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,016 | $70K |
| 64405 | <1% | 720 | $70K | |
| 90715 | <1% | 11,075 | $69K | |
| 70496 | <1% | 1,215 | $68K | |
| 90688 | <1% | 4,605 | $64K | |
| 49083 | <1% | 311 | $63K | |
| 99462 | <1% | 2,616 | $62K | |
| 74018 | <1% | 8,007 | $60K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 13,214 | $59K |
| 73630 | <1% | 10,778 | $59K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 964 | $58K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,120 | $58K |
| 82728 | <1% | 12,130 | $57K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,798 | $56K |
| 77066 | Tomosynthesis, mammo | <1% | 1,376 | $55K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 571 | $55K |
| 58300 | <1% | 1,276 | $55K | |
| 0002A | <1% | 1,501 | $54K | |
| 87653 | <1% | 2,869 | $52K | |
| G0378 | Hospital observation service, per hour | <1% | 4,359 | $52K |
| 72141 | <1% | 673 | $51K | |
| 0001A | <1% | 1,556 | $50K | |
| 93970 | <1% | 932 | $50K | |
| 99217 | <1% | 1,332 | $48K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,297 | $47K |
| 99464 | <1% | 1,102 | $47K | |
| 90474 | <1% | 8,007 | $46K | |
| 70491 | <1% | 650 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,481 | $44K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,983 | $44K |
| 10060 | <1% | 565 | $43K | |
| 80074 | <1% | 2,562 | $43K | |
| 99243 | <1% | 790 | $42K | |
| 70486 | <1% | 1,578 | $42K | |
| 86003 | <1% | 2,390 | $42K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 4,401 | $41K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14,730 | $41K |
| 58301 | <1% | 656 | $41K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 2,006 | $40K |
| 74183 | <1% | 397 | $40K | |
| 84466 | <1% | 9,304 | $40K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 943 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,327 | $38K |
| 72100 | <1% | 3,609 | $38K | |
| 93350 | <1% | 326 | $38K | |
| 87070 | <1% | 14,103 | $37K | |
| 86480 | <1% | 1,552 | $37K | |
| 81025 | <1% | 27,600 | $36K | |
| 20553 | <1% | 484 | $36K | |
| 86803 | <1% | 8,090 | $35K | |
| 88342 | <1% | 2,248 | $35K | |
| 59425 | <1% | 72 | $35K | |
| 73562 | <1% | 5,563 | $34K | |
| 84702 | <1% | 7,886 | $34K | |
| 87507 | <1% | 302 | $33K | |
| 90480 | <1% | 870 | $33K | |
| 73030 | <1% | 6,145 | $31K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 96 | $31K |
| G9007 | Coordinated care fee, scheduled team conference | <1% | 4,946 | $31K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,789 | $30K |
| 94726 | <1% | 2,889 | $30K | |
| 93017 | <1% | 1,923 | $30K | |
| 99152 | <1% | 5,522 | $29K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,565 | $29K |
| 64400 | <1% | 220 | $29K | |
| 82607 | <1% | 6,893 | $29K | |
| 84439 | <1% | 8,294 | $29K | |
| 73610 | <1% | 5,994 | $28K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,055 | $28K |
| 11750 | <1% | 309 | $27K | |
| 83970 | <1% | 1,700 | $27K | |
| 0071A | <1% | 729 | $27K | |
| 0012A | <1% | 753 | $25K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,711 | $25K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 85 | $25K |
| 11981 | <1% | 471 | $25K | |
| 73130 | <1% | 5,658 | $25K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 901 | $24K |
| 82670 | <1% | 1,975 | $24K | |
| 97165 | <1% | 630 | $24K | |
| 0124A | <1% | 863 | $24K | |
| 83540 | <1% | 10,627 | $23K | |
| 84410 | <1% | 986 | $23K | |
| 0072A | <1% | 616 | $23K | |
| 95886 | <1% | 1,181 | $23K | |
| 59899 | <1% | 327 | $22K | |
| 73502 | <1% | 3,609 | $22K | |
| 83013 | <1% | 1,049 | $21K | |
| 93016 | <1% | 1,909 | $21K | |
| 70498 | <1% | 741 | $21K | |
| 0054A | <1% | 638 | $21K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 68 | $21K |
| 73110 | <1% | 3,804 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,499 | $20K |
| 43450 | <1% | 185 | $20K | |
| 73564 | <1% | 2,708 | $19K | |
| 0011A | <1% | 752 | $19K | |
| 11721 | <1% | 1,976 | $18K | |
| 83001 | <1% | 2,278 | $18K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 765 | $18K |
| 0004A | <1% | 495 | $18K | |
| 96160 | <1% | 2,661 | $18K | |
| 87340 | <1% | 7,638 | $18K | |
| 83655 | <1% | 2,792 | $18K | |
| 74178 | <1% | 188 | $17K | |
| 95911 | <1% | 95 | $17K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 41 | $17K |
| 84146 | <1% | 2,435 | $17K | |
| 97802 | <1% | 370 | $17K | |
| 87205 | <1% | 13,216 | $17K | |
| 98966 | <1% | 12,522 | $16K | |
| 95251 | <1% | 900 | $16K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 44 | $16K |
| 51798 | <1% | 1,054 | $16K | |
| 83735 | <1% | 13,304 | $16K | |
| 82570 | <1% | 11,516 | $16K | |
| 69210 | <1% | 1,202 | $15K | |
| 0064A | <1% | 473 | $15K | |
| 87186 | <1% | 8,261 | $15K | |
| 85027 | <1% | 8,278 | $15K | |
| 92133 | <1% | 890 | $15K | |
| 83002 | <1% | 1,768 | $15K | |
| 81001 | <1% | 37,400 | $15K | |
| 85055 | <1% | 1,845 | $14K | |
| 98926 | <1% | 1,941 | $14K | |
| 92015 | Determination of refractive state | <1% | 1,659 | $14K |
| 93320 | <1% | 2,432 | $14K | |
| 99406 | <1% | 2,243 | $14K | |
| 11982 | <1% | 242 | $14K | |
| 84403 | <1% | 1,277 | $14K | |
| 93018 | <1% | 1,880 | $14K | |
| 82043 | <1% | 9,532 | $14K | |
| 83880 | <1% | 2,679 | $13K | |
| 31231 | <1% | 309 | $13K | |
| 81002 | <1% | 13,284 | $13K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 187 | $13K |
| 90656 | <1% | 1,254 | $13K | |
| 72131 | <1% | 440 | $13K | |
| 71271 | <1% | 302 | $13K | |
| 84144 | <1% | 1,665 | $13K | |
| 31575 | <1% | 271 | $12K | |
| 58558 | <1% | 22 | $12K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 749 | $12K |
| 86580 | <1% | 1,372 | $12K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 849 | $12K |
| 93298 | <1% | 853 | $12K | |
| 76870 | <1% | 681 | $12K | |
| 86850 | <1% | 8,253 | $12K | |
| 99245 | <1% | 108 | $12K | |
| 72114 | <1% | 777 | $11K | |
| 74019 | <1% | 1,429 | $11K | |
| 96127 | <1% | 10,663 | $11K | |
| 73221 | <1% | 137 | $11K | |
| 86225 | <1% | 2,618 | $10K | |
| 76641 | <1% | 279 | $10K | |
| 98967 | <1% | 5,497 | $10K | |
| 83722 | <1% | 1,172 | $10K | |
| 73140 | <1% | 1,798 | $10K | |
| 43235 | <1% | 58 | $10K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 310 | $10K |
| 97597 | <1% | 240 | $10K | |
| 86769 | <1% | 535 | $10K | |
| 82784 | <1% | 2,950 | $10K | |
| 93296 | <1% | 575 | $10K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 385 | $10K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 39 | $9K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,024 | $9K |
| 86762 | <1% | 3,455 | $9K | |
| 86376 | <1% | 1,749 | $9K | |
| 82746 | <1% | 1,904 | $9K | |
| 88307 | <1% | 886 | $9K | |
| 94729 | <1% | 3,896 | $9K | |
| 81003 | <1% | 11,573 | $9K | |
| 72040 | <1% | 989 | $9K | |
| 86787 | <1% | 3,517 | $9K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 25 | $9K |
| 99219 | <1% | 122 | $8K | |
| 84481 | <1% | 1,177 | $8K | |
| 86038 | <1% | 2,447 | $8K | |
| 97803 | <1% | 316 | $8K | |
| 87077 | <1% | 4,184 | $8K | |
| 73590 | <1% | 1,972 | $8K | |
| 86140 | <1% | 5,833 | $8K | |
| 85610 | <1% | 10,188 | $8K | |
| 80076 | <1% | 5,480 | $8K | |
| 72050 | <1% | 808 | $8K | |
| 72110 | <1% | 915 | $8K | |
| 57454 | <1% | 78 | $8K | |
| 87529 | <1% | 709 | $7K | |
| 82950 | <1% | 2,805 | $7K | |
| 86141 | <1% | 2,128 | $7K | |
| 93244 | <1% | 552 | $7K | |
| 85018 | <1% | 5,540 | $7K | |
| 87088 | <1% | 3,710 | $7K | |
| 94010 | <1% | 1,381 | $7K | |
| 84480 | <1% | 1,154 | $7K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 684 | $6K |
| 92557 | <1% | 876 | $6K | |
| 92083 | <1% | 222 | $6K | |
| 74174 | <1% | 66 | $6K | |
| 87081 | <1% | 5,327 | $6K | |
| 73560 | <1% | 1,537 | $6K | |
| 83993 | <1% | 604 | $6K | |
| 83516 | <1% | 1,356 | $6K | |
| 99254 | <1% | 61 | $6K | |
| 84703 | <1% | 5,164 | $6K | |
| 90662 | <1% | 629 | $5K | |
| 98927 | <1% | 972 | $5K | |
| 93242 | <1% | 424 | $5K | |
| 82248 | <1% | 11,814 | $5K | |
| 86200 | <1% | 1,373 | $5K | |
| 92551 | <1% | 1,663 | $5K | |
| 84153 | <1% | 761 | $5K | |
| 87147 | <1% | 4,563 | $5K | |
| 86431 | <1% | 2,961 | $5K | |
| 76937 | <1% | 1,130 | $5K | |
| 83690 | <1% | 13,947 | $4K | |
| 93325 | <1% | 3,507 | $4K | |
| 86364 | <1% | 1,191 | $4K | |
| 71101 | <1% | 541 | $4K | |
| 99397 | <1% | 135 | $4K | |
| 86706 | <1% | 1,112 | $4K | |
| 88304 | <1% | 1,648 | $4K | |
| 0134A | <1% | 172 | $4K | |
| 90473 | <1% | 426 | $4K | |
| 98968 | <1% | 1,478 | $4K | |
| 86901 | <1% | 9,148 | $4K | |
| 76882 | <1% | 77 | $4K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,284 | $4K |
| 85652 | <1% | 4,929 | $3K | |
| 99221 | <1% | 70 | $3K | |
| 86696 | <1% | 471 | $3K | |
| 95713 | <1% | 13 | $3K | |
| 93308 | <1% | 93 | $3K | |
| 93000 | <1% | 404 | $3K | |
| 72197 | <1% | 24 | $3K | |
| 99421 | <1% | 329 | $3K | |
| 99459 | <1% | 277 | $3K | |
| 98925 | <1% | 531 | $3K | |
| 73080 | <1% | 631 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 747 | $3K |
| 93227 | <1% | 209 | $3K | |
| 0081A | <1% | 86 | $3K | |
| 84550 | <1% | 1,975 | $3K | |
| 93880 | <1% | 54 | $3K | |
| 82247 | <1% | 1,033 | $3K | |
| 85730 | <1% | 5,163 | $3K | |
| 90679 | <1% | 12 | $3K | |
| 80069 | <1% | 753 | $3K | |
| 82105 | <1% | 555 | $3K | |
| 11045 | <1% | 237 | $3K | |
| 88341 | <1% | 1,187 | $3K | |
| 73700 | <1% | 86 | $3K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 362 | $3K |
| 85651 | <1% | 2,879 | $3K | |
| 72202 | <1% | 441 | $3K | |
| 88112 | <1% | 322 | $3K | |
| 99417 | Prolong home eval add 15m | <1% | 119 | $3K |
| 73070 | <1% | 665 | $3K | |
| 90632 | <1% | 651 | $3K | |
| 86704 | <1% | 648 | $3K | |
| 83014 | <1% | 1,048 | $3K | |
| 73090 | <1% | 621 | $2K | |
| 93225 | <1% | 52 | $2K | |
| 83615 | <1% | 1,291 | $2K | |
| 86695 | <1% | 471 | $2K | |
| 82565 | <1% | 1,863 | $2K | |
| 72070 | <1% | 215 | $2K | |
| 84100 | <1% | 2,725 | $2K | |
| 92567 | <1% | 2,211 | $2K | |
| 86160 | <1% | 512 | $2K | |
| 0154A | <1% | 60 | $2K | |
| 76818 | <1% | 29 | $2K | |
| 86235 | <1% | 107 | $2K | |
| 86812 | <1% | 289 | $2K | |
| 84156 | <1% | 1,621 | $2K | |
| 82550 | <1% | 1,421 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 113 | $2K |
| 90744 | <1% | 179 | $2K | |
| 51701 | <1% | 581 | $2K | |
| 82977 | <1% | 778 | $2K | |
| 86665 | <1% | 376 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12,897 | $2K |
| 0074A | <1% | 63 | $2K | |
| 0051A | <1% | 46 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,300 | $2K |
| 90672 | <1% | 369 | $2K | |
| 86308 | <1% | 1,198 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,426 | $2K |
| 92587 | <1% | 12 | $2K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 63 | $1K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 208 | $1K |
| 0052A | <1% | 40 | $1K | |
| 86694 | <1% | 250 | $1K | |
| 86255 | <1% | 349 | $1K | |
| 10022 | <1% | 15 | $1K | |
| 84425 | <1% | 217 | $1K | |
| 82627 | <1% | 110 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,343 | $1K |
| 99487 | Ccm add 20min | <1% | 67 | $1K |
| 85379 | <1% | 2,859 | $1K | |
| 92552 | <1% | 85 | $1K | |
| 90714 | <1% | 623 | $1K | |
| 69209 | <1% | 318 | $1K | |
| 87045 | <1% | 254 | $1K | |
| 74021 | <1% | 202 | $1K | |
| 0031A | <1% | 29 | $1K | |
| 92136 | <1% | 51 | $992.69 | |
| 95700 | <1% | 13 | $988.83 | |
| 96417 | <1% | 41 | $963.04 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 10,300 | $961.45 |
| 72128 | <1% | 25 | $951.06 | |
| 96415 | <1% | 22 | $900.41 | |
| 87807 | <1% | 240 | $867.06 | |
| 82533 | <1% | 123 | $854.92 | |
| 87400 | <1% | 3,232 | $852.10 | |
| 73552 | <1% | 184 | $830.02 | |
| 86800 | <1% | 128 | $824.82 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 233 | $810.71 |
| G0008 | Administration of influenza virus vaccine | <1% | 1,351 | $799.94 |
| 97014 | <1% | 105 | $785.65 | |
| 87109 | <1% | 108 | $763.88 | |
| 0003A | <1% | 21 | $757.00 | |
| 86008 | <1% | 13 | $749.47 | |
| 76857 | <1% | 23 | $723.22 | |
| 86664 | <1% | 189 | $720.77 | |
| 99441 | <1% | 93 | $718.60 | |
| 87563 | <1% | 88 | $707.02 | |
| 90707 | <1% | 7,794 | $698.60 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 13 | $679.86 |
| 92002 | <1% | 17 | $667.32 | |
| 84155 | <1% | 585 | $651.69 | |
| 73660 | <1% | 141 | $639.47 | |
| 86663 | <1% | 189 | $618.63 | |
| 87420 | <1% | 1,080 | $613.76 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,058 | $613.20 |
| 82951 | <1% | 76 | $591.37 | |
| 73521 | <1% | 48 | $591.18 | |
| 86039 | <1% | 301 | $579.64 | |
| 87220 | <1% | 529 | $563.08 | |
| 84484 | <1% | 11,763 | $508.12 | |
| 80164 | <1% | 111 | $474.27 | |
| 84590 | <1% | 88 | $446.61 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,095 | $435.71 |
| 80178 | <1% | 182 | $405.73 | |
| 87449 | <1% | 93 | $403.77 | |
| 11900 | <1% | 15 | $389.90 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 36 | $387.80 |
| 84165 | <1% | 106 | $366.37 | |
| 99442 | <1% | 40 | $359.06 | |
| 72170 | <1% | 56 | $351.21 | |
| 17000 | <1% | 14 | $345.13 | |
| 83021 | <1% | 81 | $317.99 | |
| 93321 | <1% | 117 | $317.94 | |
| 87493 | <1% | 27 | $312.71 | |
| 87075 | <1% | 371 | $308.10 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 96 | $299.42 |
| 11102 | <1% | 15 | $295.69 | |
| 95249 | <1% | 13 | $286.92 | |
| 72220 | <1% | 43 | $278.12 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,914 | $270.82 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 40 | $243.43 |
| 81000 | <1% | 345 | $235.66 | |
| 94760 | <1% | 24,177 | $218.81 | |
| 84154 | <1% | 38 | $208.74 | |
| 93248 | <1% | 14 | $207.76 | |
| 92250 | <1% | 12 | $203.22 | |
| 76942 | <1% | 13 | $200.53 | |
| 87040 | <1% | 859 | $200.40 | |
| 85014 | <1% | 5,415 | $182.72 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 739 | $178.94 |
| 92555 | <1% | 88 | $176.24 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,097 | $175.04 |
| 82952 | <1% | 75 | $168.94 | |
| 85046 | <1% | 81 | $165.78 | |
| 12001 | <1% | 266 | $164.30 | |
| 85660 | <1% | 66 | $150.16 | |
| 76377 | <1% | 33 | $143.16 | |
| 12002 | <1% | 53 | $141.76 | |
| 93922 | <1% | 17 | $135.05 | |
| 73060 | <1% | 44 | $133.98 | |
| 93246 | <1% | 14 | $133.04 | |
| 84080 | <1% | 39 | $130.79 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 130 | $126.94 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,165 | $121.60 |
| 86618 | <1% | 26 | $108.56 | |
| 82310 | <1% | 96 | $105.27 | |
| 87324 | <1% | 29 | $104.44 | |
| 83605 | <1% | 2,607 | $103.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 6,968 | $100.59 |
| 73600 | <1% | 21 | $90.89 | |
| 82103 | <1% | 26 | $87.08 | |
| 82378 | <1% | 13 | $82.15 | |
| 87328 | <1% | 12 | $77.42 | |
| 73620 | <1% | 19 | $75.19 | |
| 29125 | <1% | 14 | $74.88 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $71.04 |
| 90696 | <1% | 3,440 | $69.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 77 | $68.08 |
| 87329 | <1% | 12 | $67.14 | |
| 98928 | <1% | 58 | $66.96 | |
| 12011 | <1% | 39 | $66.17 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,136 | $63.13 |
| 36000 | <1% | 6,805 | $63.02 | |
| 83525 | <1% | 12 | $62.50 | |
| 82272 | <1% | 52 | $59.42 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 689 | $57.48 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 3,740 | $53.65 |
| 80047 | <1% | 5,206 | $53.54 | |
| 82085 | <1% | 12 | $53.25 | |
| 82652 | <1% | 15 | $52.32 | |
| A9270 | Non-covered item or service | <1% | 32,466 | $40.38 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 152 | $40.22 |
| 87102 | <1% | 43 | $38.12 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 86 | $36.58 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,882 | $35.43 |
| 87641 | <1% | 33 | $34.66 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 81 | $33.00 |
| 84132 | <1% | 24 | $32.31 | |
| 87210 | <1% | 27 | $26.03 | |
| 82140 | <1% | 12 | $25.56 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 152 | $23.43 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,727 | $22.06 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 525 | $21.91 |
| 82150 | <1% | 13 | $21.34 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,672 | $20.29 |
| 83520 | <1% | 27 | $19.09 | |
| 96376 | <1% | 2,362 | $18.77 | |
| 95012 | <1% | 120 | $16.00 | |
| 85045 | <1% | 13 | $15.81 | |
| 93041 | <1% | 3,174 | $15.64 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 74 | $14.02 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,784 | $11.74 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,328 | $11.16 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 1,627 | $10.41 |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 12 | $10.34 |
| 89051 | <1% | 50 | $7.34 | |
| 82010 | <1% | 26 | $4.78 | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,561 | $3.49 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 380 | $3.00 |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,072 | $2.25 |
| J1815 | Injection, insulin, per 5 units | <1% | 2,387 | $2.12 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 16 | $0.00 |
| 90700 | 0% | 4,738 | $0.00 | |
| A4565 | Slings | 0% | 1,984 | $0.00 |
| 90633 | 0% | 8,522 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 517 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 370 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 15,803 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 8,879 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 602 | $0.00 |
| 90681 | 0% | 6,517 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 473 | $0.00 |
| 90713 | 0% | 795 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 535 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 93 | $0.00 |
| C1729 | Catheter, drainage | 0% | 684 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,177 | $0.00 |
| 99173 | 0% | 800 | $0.00 | |
| 90648 | 0% | 909 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 25 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 321 | $0.00 |
| 82800 | 0% | 153 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 51 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 207 | $0.00 |
| 88173 | 0% | 76 | $0.00 | |
| 90685 | 0% | 96 | $0.00 | |
| 84145 | 0% | 57 | $0.00 | |
| C1780 | Lens, intraocular (new technology) | 0% | 18 | $0.00 |
| 99001 | 0% | 16 | $0.00 | |
| 76000 | 0% | 12 | $0.00 | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 21 | $0.00 |
| C1769 | Guide wire | 0% | 1,974 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 3,572 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 850 | $0.00 |
| 90723 | 0% | 11,458 | $0.00 | |
| 90647 | 0% | 10,706 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 506 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 5,967 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,048 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,278 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 7,396 | $0.00 |
| 90698 | 0% | 161 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 2,693 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,937 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 782 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,195 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 633 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 2,632 | $0.00 |
| 90680 | 0% | 399 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 252 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 105 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 49 | $0.00 |
| 88300 | 0% | 176 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 127 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 479 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 12 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 298 | $0.00 |
| 91318 | 0% | 25 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 152 | $0.00 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 67 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 28 | $0.00 |
| 91319 | 0% | 59 | $0.00 | |
| 96368 | 0% | 18 | $0.00 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 45 | $0.00 |
| 36416 | 0% | 28 | $0.00 | |
| 90660 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUSSIAN, MISTY (MANAGER, PROVIDER ENROLLMENT)
| Provider | Location | Paid |
|---|---|---|
| Edward W Sparrow Hospital Association | Lansing, MI | $125.88M |
| Sparrow Ionia Hospital | Ionia, MI | $13.76M |
| Sparrow Eaton Hospital | Charlotte, MI | $13.22M |
| Sparrow Clinton Hospital | Saint Johns, MI | $8.68M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $5.81M |
| Sparrow Carson Hospital | Carson City, MI | $5.48M |
| Edward W. Sparrow Hospital Association | East Lansing, MI | $5.43M |
| Sparrow Ionia Hospital | Ionia, MI | $3.49M |
| Sparrow Eaton Hospital | Charlotte, MI | $3.12M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $2.77M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $2.61M |
| Edward W Sparrow Hospital Association | Lansing, MI | $2.48M |
| Edward W. Sparrow Hospital Association | Mason, MI | $2.44M |
| Sparrow Community Care | Lansing, MI | $2.31M |
| Edward W Sparrow Hospital Association | Lansing, MI | $2.31M |
| Edward W Sparrow Hospital Association | Lansing, MI | $1.85M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $1.83M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $1.65M |
| Sparrow Ionia Hospital | Portland, MI | $1.61M |
| Sparrow Carson Hospital | Ithaca, MI | $1.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.